for adverse events (CTCAE) V4.0 grades. Mean adherence at 96 weeks was calculated by the medication possession ratio based on pharmacy refill records.

Results Thirty-three patients started alirocumab treatment in 2017 and 31 (93.9%) were still on treatment after 96 weeks. Two patients (6.1%) discontinued therapy: one due to an active malignancy and one due to loss of follow-up.

Patient characteristics were 58.1% men with a median (IQR) age of 65 (11) years. Alirocumab dose was 75 mg/2 weeks in 87.1% of patients and 150 mg/2 weeks in 12.9%. Secondary prevention was 83.9% and there was a high cardiovascular risk in 80.6%. Type of hypercholesterolaemia was heterozygous familial in 29.0% of patients, polygenic in 67.7% and combined familial hyperlipidaemia in 3.2%. Statin intolerance was found in 38.7% of patients. Comorbidities included diabetes mellitus 19.4%, hypertension 54.8% and smoking 3.2%.

Median (range) adherence was 100% (81.7–100%) (only 2 patients (6.5%) with adherence <90%). Median (IQR) reduction in LDL-c reduction was 59.5 (22.6)%. Only one patient did not have a reduction in LDL from baseline (adherence 82%). A high cardiovascular risk was the only patient factor associated with 100% adherence ($p=0.034$). Mild adverse effects were present in 19.3% of patients (27.3% constipation, 18.2% flu-like syndrome, 18.2% pruritus and other (dizziness, palpitations, headache, dysgeusia) 9.1% each). All adverse effects (100%) were classified as CTCAE grade 1.

Conclusion and relevance More than 90% of patients starting alirocumab persisted with treatment for 96 weeks after initiation. Alirocumab showed good long term efficacy with a median reduction in LDL of >50%. It was also well tolerated because all reported adverse events were mild and did not lead to any treatment discontinuation.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

4CPS-024 EFFECTIVENESS OF ANTI-INTERLEUKIN-17 DRUGS IN PSORIASIS IN CLINICAL PRACTICE

¹A Retamero Delgado*, ²C Seguí Solanes, ¹V Charques Trallero, ¹S Mendiola García, ²N Rudi Sola, ¹D Ferrandez Martí. ¹Consorti Sanitari De L'anoia, Pharmacy, Igualada, Spain; ²Hospital General De Granollers, Pharmacy, Granollers, Spain

10.1136/ejhp-pharm-2020-eahpconf.125

Background and importance Anti-interleukin-17 (IL-17) drugs are a new option for treating patients with psoriasis which have demonstrated high efficacy in clinical trials.

Aim and objectives To analyse the effectiveness of anti-IL-17 drugs for psoriasis in clinical practice.

Material and methods A cross sectional study was conducted in two regional hospitals with a total of 196 biologic treatments (BT) for psoriasis. Inclusion criteria were patients in active treatment for at least 12 weeks with an anti-IL-17 drug (secukinumab or ixekizumab) for psoriasis until October 2019. Data collected included patient characteristics, type of psoriasis, previous and actual treatment, effectiveness measured by the psoriasis area severity index (PASI) and the impact on quality of life measured by the dermatology life quality index (DLQI). Statistical analysis was carried out with SPSS Statistics V22. Results are presented as mean (SD) for quantitative data and percentages for qualitative data.

Abstract 4CPS-024 Table 1

	Previous	Post	P value
PASI	12.5 (5.7)	0.9 (1.3)	<0.001
DLQI	10.0 (7.4)	0.6 (1.1)	<0.001

Results Thirty patients were included in the study (15.3% of the total BT for psoriasis in both hospitals), 16 (53.3%) of whom were men, and mean age was 50.2 (13.6) years.

Distribution by types of psoriasis: 30 (100.0%) plaque, 7 (23.3%) nail, 6 (20.0%) palmoplantar, 6 (20.0%) scalp and 2 (6.6%) inverse psoriasis. Thirteen (43.3%) patients had more than one type.

Distribution by treatment: 23 (76.7%) secukinumab and 7 (23.3%) ixekizumab. Twenty-three (76.7%) patients had received at least one systemic agent, which was usually methotrexate (69.6%), followed by acitretin (26.1%) and ciclosporin (4.4%). Moreover, for 13 (43.3%) patients, the anti-IL-17 drug was the first BT, while in 17 (56.7%) there had been another BT previously. Two (6.7%) patients had previously received an anti-IL-17 drug, which in both cases was secukinumab. Effectiveness is shown in table 1.

Twenty-two (73.3%) patients achieved a PASI of 90 (almost complete clearance of psoriatic lesions) and 24 (80.0%) had a DLQI ≤1 (no impact on quality of life) within 12 weeks of treatment. No significant differences in previous and actual PASI and DLQI were found between secukinumab and ixekizumab.

Conclusion and relevance

- More than half of the patients had more than only plaque psoriasis.
- Most patients had been treated previously with one systemic treatment.
- Anti-IL-17 drugs were effective in clinical practice.
- There were no differences between secukinumab and ixekizumab in terms of effectiveness.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

4CPS-025 DUPILUMAB IN THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS: CASE REPORTS

C Palomo-Palomo*, MM Romero Alonso, D Guerra Estevez, M Barrera Ledesma, J Estaire Gutierrez. Hospital Infanta Elena, Hospital Pharmacy, Huelva, Spain

10.1136/ejhp-pharm-2020-eahpconf.126

Background and importance Dupilumab is authorised in the European Union for the treatment of moderate to severe atopic dermatitis (AD) in adult patients who are candidates for systemic treatment. It is a non-funded drug in Spain, so patients can only access this treatment through medication management under special circumstances according to the Spanish Agency for Medicines and Health Products (AEMPS).

Aim and objectives To analyse the criteria for use, effectiveness and economic impact of dupilumab in the treatment of moderate to severe AD.